# Therapeutic Decision-Making for Respiratory Infections in Cattle ## Key Takeaways - Bovine Respiratory Disease (BRD) is a multifactorial complex initiated by viral cofactors (e.g., BHV-1, BRSV, PI-3, BVDV) that suppress host immunity, creating an opportunity for opportunistic bacterial pathogens like *Mannheimia hemolytica* to cause fibrinous pneumonia. - Early therapeutic intervention in acute BRD cases, defined by fever, depression, reduced appetite, and increased respiratory effort, is critical to prevent irreversible pulmonary consolidation and improve treatment outcomes. - Antimicrobial selection for BRD should be guided by expected pathogen susceptibility, pharmacokinetic properties, route of administration, withdrawal periods, and regional resistance patterns, with no single class being universally superior. - Monitoring treatment response at 48 to 72 hours post-initiation is essential, with persistent fever, worsening respiratory effort, or declining appetite triggering reassessment of diagnosis, pathogen, and drug choice. - Supportive care, including anti-inflammatory therapy (NSAIDs), fluid therapy, and environmental management (clean bedding, reduced stocking density), is crucial to address physiological derangements and support recovery alongside antimicrobial treatment. - Treatment failure necessitates a structured reassessment of the diagnosis, drug delivery, potential resistance, complications (e.g., abscessation, pleuritis), and host factors (e.g., immunosuppression, poor nutrition) rather than empirical drug switching. --- Respiratory disease in cattle remains the most economically significant infectious disease complex affecting beef and dairy production worldwide. This article provides a structured framework for therapeutic decision-making, from initial case assessment through antimicrobial selection, adjunctive therapy, and monitoring of treatment response. It is written for veterinary students and practitioners who need a systematic approach to a disease process that is frequently multifactorial, time-sensitive, and complicated by variable pathogen involvement, host immune status, and production setting. The clinical question this article addresses is direct: how does a veterinarian decide whether to treat, what to treat with, when to re-evaluate, and when to stop? The answer requires integrating knowledge of the pathogens involved, the pharmacology of available drug classes, the physiological markers of disease resolution, and the practical constraints of cattle handling and economics. Later parts of this article will cover antimicrobial selection in detail, adjunctive and supportive therapy, and monitoring protocols. This first part establishes the conceptual foundation: the pathogenic basis of bovine respiratory disease, the diagnostic reasoning that precedes treatment, and the principles that govern therapeutic choices. ## At a Glance | Parameter | Decision Point | Clinical Relevance | |---|---|---| | Primary bacterial pathogen | *Mannheimia hemolytica* is the most frequent isolate from pneumonic lung | Guides empirical antimicrobial selection and expectation of fibrinous pneumonia | | Viral cofactors | BHV-1, BRSV, PI-3, BVDV predispose to bacterial invasion | Explains why antimicrobials alone may fail and why vaccination history matters | | Treatment timing | Early intervention in acute cases improves response | Delayed therapy allows irreversible pulmonary consolidation | | Case definition | Fever, depression, reduced appetite, respiratory effort | Objective criteria reduce both under-treatment and unnecessary treatment | | Antimicrobial class choice | Based on pathogen susceptibility, label indication, and withdrawal period | No single class is universally superior, resistance patterns vary by region and operation | | Monitoring interval | Re-evaluate at 48 to 72 hours after treatment initiation | Allows assessment of response before committing to a second antimicrobial course | | Failure criteria | Persistent fever, worsening respiratory effort, declining appetite | Triggers re-examination of diagnosis, pathogen, and drug choice | ## The Pathogenic Basis of Bovine Respiratory Disease Bovine respiratory disease (BRD) is not a single infection but a complex interaction of host defenses, viral pathogens, and bacterial opportunists. The upper respiratory tract of cattle normally harbors commensal bacteria, including *Mannheimia hemolytica*, which resides in the nasopharynx without causing disease. Disease develops when host defenses are compromised, allowing these commensals to gain access to the lower airways and proliferate [Mannheimia hemolytica and bovine respiratory disease](https://pubmed.ncbi.nlm.nih.gov/18218156/). Viral infection is a common initiating event. Bovine herpesvirus type 1 (BHV-1) is particularly significant because it suppresses multiple arms of the immune response, including interferon-dependent transcription, CD8+ T-cell recognition of infected cells, and lymphocyte homing to infection sites. This immune suppression creates a window during which bacterial invasion of the lung can occur [the role of BHV-1 in the bovine respiratory disease complex](https://pubmed.ncbi.nlm.nih.gov/18218160/). The practical implication is that a respiratory outbreak in a group of cattle often reflects an underlying viral epidemic, and antimicrobial therapy alone will not resolve the predisposing cause. The bacterial component determines the character of the pulmonary lesion. *M. hemolytica* produces a leukotoxin that destroys neutrophils and other leukocytes infiltrating the lung, impairing bacterial clearance and contributing to the development of fibrinous pneumonia [Mannheimia hemolytica and bovine respiratory disease](https://pubmed.ncbi.nlm.nih.gov/18218156/). This explains why clinical signs can progress rapidly from mild depression to severe respiratory distress with toxemia, and why early intervention is critical. *Pasteurella multocida*, *Histophilus somni*, and *Mycoplasma bovis* are also isolated from pneumonic lungs, and their relative importance varies by region, production system, and stage of the feeding period. ## Diagnostic Reasoning Before Treatment The decision to treat begins with a case definition. Fever, depression, reduced feed intake, and increased respiratory effort are the core clinical findings. Rectal temperature is the most objective and repeatable measurement available in field conditions, and it should be recorded for every suspect animal. A single elevated temperature in a group of cattle with known respiratory disease exposure is sufficient to justify treatment in most production settings. The diagnostic question is whether the disease is bacterial, viral, or mixed, and whether complications such as lung abscessation or pleuritis are present. Thoracic auscultation is insensitive for detecting early pneumonia, and normal lung sounds do not exclude significant disease. Ultrasonography, where available, provides more reliable detection of consolidation and pleural effusion. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides detailed guidance on the clinical examination of the bovine respiratory tract, including interpretation of auscultatory findings and indications for advanced imaging. Nasal swabs have limited predictive value for identifying the causative bacterial pathogen, because the organizms responsible for pneumonia are often present as commensals in the upper airway. Deep nasopharyngeal or transtracheal wash samples are more informative but are rarely practical in production settings. The decision to treat empirically is therefore justified in most cases, provided the veterinarian revisits the diagnosis if the animal fails to respond. ## Principles of Antimicrobial Selection Antimicrobial therapy for BRD is directed at the bacterial component of the disease complex. The choice of drug class should be guided by the expected pathogen profile, the pharmacokinetic properties of the drug, the route of administration, the withdrawal period, and the susceptibility patterns of bacteria isolated from the operation or region. The efficacy of antimicrobials varies because of inconsistencies in diagnosis and treatment regimes and the development of antibiotic resistance [Mannheimia hemolytica and bovine respiratory disease](https://pubmed.ncbi.nlm.nih.gov/18218156/). Several drug classes are licensed for BRD in cattle, including tetracyclines, macrolides, fluoroquinolones, cephalosporins, and phenicols. No single class is universally superior, and the choice depends on the clinical scenario. For a first-case animal with acute disease and no prior antimicrobial exposure, a drug with good activity against *M. hemolytica* and *P. multocida* is appropriate. For a chronically affected animal that has failed previous therapy, culture and susceptibility testing of a deep respiratory sample should be pursued if possible. Current formulary and label references must be consulted for specific doses, routes, and withdrawal periods, as these vary by drug, formulation, and jurisdiction. The veterinarian is responsible for ensuring that any antimicrobial use complies with the label and with local regulatory requirements. ## The Role of Metaphylaxis and Group-Level Decisions In high-risk groups, such as newly received feedlot calves, metaphylactic antimicrobial administration at arrival reduces morbidity and mortality from BRD. This practice is effective, but it raises concerns about antimicrobial resistance and public perception [recent advances in management of highly stressed, newly received feedlot cattle](https://pubmed.ncbi.nlm.nih.gov/17085724/). The decision to use metaphylaxis should be based on the risk profile of the group, including source, transport distance, vaccination history, and weather stress, instead of applied as a routine to all cattle. Group-level decisions also include vaccination strategy. Preconditioning programs that include preweaning viral vaccination and castration can significantly decrease BRD in the cattle feeding industry [recent advances in management of highly stressed, newly received feedlot cattle](https://pubmed.ncbi.nlm.nih.gov/17085724/). The veterinarian should consider whether the current outbreak reflects a failure of prevention, and whether changes to the vaccination or management program are indicated after the acute cases are treated. ## Monitoring the Response to Therapy The decision to continue, change, or stop therapy rests on serial assessment of the patient. A single examination at the time of diagnosis establishes the baseline. Subsequent examinations must be scheduled and their findings compared against that baseline, not against an idealized recovery curve. ### Clinical Parameters and Their Limitations Rectal temperature, respiratory rate and effort, appetite, and attitude form the core of routine monitoring. Temperature is the most objective of these, but it is also the most misleading when used alone. A falling temperature can indicate resolution of infection or progression to endotoxic shock with peripheral vasoconstriction. Interpret temperature trends alongside perfusion parameters such as mucous membrane color, capillary refill time, and hydration status. Respiratory rate and effort are more specific to the respiratory tract but are influenced by heat stress, pain, and acidosis. Serial assessment of lung auscultation findings is valuable, yet the absence of audible changes does not exclude pneumonia. Consolidated cranioventral lung regions may be silent on auscultation while dorsal lung regions hyperinflate and transmit sounds that obscure the lesion. Appetite and rumen fill are practical indicators in cattle. A ruminant that resumes eating and ruminating is recovering. Conversely, a bovine that remains anorexic after 48 hours of appropriate therapy warrants reassessment of the diagnosis, the drug choice, or the presence of a complication such as abscessation or fibrinous pleuritis. ### Acute Phase Proteins as Adjuncts Serum haptoglobin and serum amyloid A rise within hours of an inflammatory stimulus and fall as the stimulus resolves. These measurements can support clinical judgment, particularly in group-level health monitoring where individual examination findings are ambiguous. Their role in cattle is less established than in some other species, and they are non-specific indicators of inflammation instead of markers of bacterial infection specifically. Use them as adjuncts to clinical examination, not as replacements for it. The application of acute phase protein measurements in veterinary clinical chemistry has been reviewed in the context of herd health surveillance and prognosis in respiratory disease ([Petersen et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15099494/)). ### The 48 to 72 Hour Recheck The first scheduled recheck should occur at 48 to 72 hours after treatment initiation. This interval allows time for the antimicrobial to reach therapeutic concentrations and for the host response to begin. A patient that shows clear improvement at this point continues on the current plan. A patient that is unchanged or worse requires a full reassessment. The reassessment includes repeat thoracic auscultation, ultrasonography if available, and re-evaluation of the original diagnostic hypotheses. Consider whether the pathogen is resistant to the chosen drug, whether the drug has reached the site of infection, whether a viral component is now dominant, or whether a non-infectious differential such as congestive heart failure or interstitial pneumonia has been overlooked. | Monitoring Parameter | What It Detects | Action Threshold | Limitation | | --- | --- | --- | --- | | Rectal temperature | Systemic inflammation, endotoxemia | No improvement or rise at 48 h | Falls in shock, diurnal variation | | Respiratory rate and effort | Pulmonary lesion progression, pleural effusion | Worsening at 48 h | Affected by heat, pain, acidosis | | Appetite and rumen fill | Return of gastrointestinal function | No improvement at 48 h | Non-specific, affected by pain | | Mucous membrane color and CRT | Perfusion, endotoxemia | Pale, injected, or prolonged CRT | Late indicator of deterioration | | Lung auscultation | Consolidation, effusion, bronchial tones | New adventitious sounds | Silent lesions, dorsal compensation | | Haptoglobin / serum amyloid A | Inflammatory burden | Rising or persistently elevated | Non-specific, not point-of-care in most settings | ## When to Change Therapy The decision to switch antimicrobials requires a defined rationale. Common reasons include clinical deterioration despite therapy, isolation of a resistant organizm from a diagnostic sample, and adverse drug reactions. Each reason leads to a different choice. Clinical deterioration at the 48 hour recheck prompts a change to a drug from a different antimicrobial class, not a dose escalation of the same class. Cross-resistance within a class is common, and increasing the dose of a failing drug risks toxicity without improving efficacy. If diagnostic samples were collected before treatment, culture and susceptibility results may now be available. Use these results to guide the switch. If no samples were collected, collect them now before changing therapy. The choice of second-line therapy depends on the drugs used initially. A bovine treated with a macrolide that fails may respond to a fluoroquinolone or a cephalosporin. The reverse sequence is equally valid. The key principle is class rotation with attention to the susceptibility patterns of Mannheimia hemolytica, the principal bacterial isolate in feedlot respiratory disease ([Rice et al., 2007](https://pubmed.ncbi.nlm.nih.gov/18218156/)). ## Supportive Care and Adjunctive Therapy Antimicrobials alone do not restore a severely affected bovine to health. Supportive care addresses the physiological derangements that perpetuate disease. ### Anti-Inflammatory Therapy Non-steroidal anti-inflammatory drugs reduce fever, improve appetite, and attenuate the inflammatory response to bacterial toxins. They are indicated in patients with high fever, marked depression, or suspected endotoxemia. The decision to use them balances these benefits against the risks of abomasal ulceration and renal compromise, particularly in dehydrated animals. Correct dehydration before administering NSAIDs. ### Fluid Therapy and Nutritional Support Dehydrated cattle benefit from oral or intravenous fluids. The route depends on the severity of dehydration and the availability of equipment. Mildly dehydrated animals with a functional rumen can receive oral electrolytes. Severely dehydrated or endotoxic animals require intravenous crystalloids. Rumen fill and fecal output guide the response to fluid therapy. ### Nursing and Environment Cattle with respiratory disease benefit from clean, dry bedding, protection from wind and precipitation, and reduced stocking density. These measures reduce further respiratory challenge and allow the patient to rest. They are inexpensive, low-risk interventions that support recovery. ## Duration of Therapy and Criteria for Stopping The optimal duration of antimicrobial therapy for bovine respiratory disease is not fixed. It depends on the pathogen, the drug, the severity of disease, and the response to treatment. The trend in veterinary medicine is toward shorter courses for uncomplicated cases, but the evidence base in cattle is limited. A practical approach is to continue antimicrobial therapy until the patient has been afebrile, eating, and clinically improving for at least 24 to 48 hours. This criterion is simple to apply in individual animals. For group-level treatment, the criterion shifts to the proportion of the group requiring retreatment and the rate of new cases. Stopping therapy too early risks relapse. Continuing therapy too long selects for resistance and adds cost. The decision to stop should be documented with the clinical findings that support it. ## Documentation and Communication The treatment record should include the signalment, the clinical findings at diagnosis, the drugs used with route and duration, the monitoring parameters and their trends, and the criteria used to stop or change therapy. This record serves multiple purposes. It supports continuity of care if another clinician assumes responsibility for the case. It provides data for herd-level antimicrobial stewardship reviews. It documents the clinical reasoning behind therapeutic decisions. For group-level decisions, maintain records of morbidity, mortality, and retreatment rates. These metrics identify problems in the management system, also in individual animals. The epidemiology of bovine tuberculosis illustrates how respiratory disease transmission within and between species depends on management and environmental factors ([O'Reilly and Daborn, 1995](https://pubmed.ncbi.nlm.nih.gov/7579326/)). Similar principles apply to the bacterial and viral agents of the bovine respiratory disease complex, where stress and commingling drive transmission. ## Decision Framework for Treatment Failure When a bovine fails to respond to initial therapy, work through a structured differential list instead of switching drugs empirically without reflection. First, verify the diagnosis. Confirm that the patient has bacterial pneumonia and not a viral pneumonia, interstitial pneumonia, congestive heart failure, or a non-respiratory disease with similar signs. Thoracic ultrasonography and diagnostic sampling are valuable at this stage. Second, verify drug delivery. Confirm that the drug was administered at the correct dose, by the correct route, and that the full dose was retained. Subcutaneous injections that leak, intravenous injections that extravasate, and oral medications that are regurgitated all reduce effective dose. Third, consider pharmacokinetic failure. Some drugs penetrate pulmonary tissue and bronchial secretions better than others. A drug that is active in vitro may be ineffective in vivo if it does not reach the site of infection in sufficient concentration. Fourth, consider resistance. If the pathogen is resistant to the drug class, no dose adjustment will produce a cure. Culture and susceptibility testing are the definitive methods for identifying resistance. Fifth, consider complications. Pulmonary abscessation, fibrinous pleuritis, and bronchopneumonia with extensive consolidation respond poorly to antimicrobials alone. These complications may require prolonged therapy, surgical drainage in the case of abscesses, or culling in severe cases. Finally, consider host factors. Immunosuppression from concurrent viral infection, bovine viral diarrhea virus persistence, or poor nutritional status impairs the response to therapy. The interaction between viral pathogens and bacterial invasion is central to the pathogenesis of bovine respiratory disease ([Jones and Chowdhury, 2007](https://pubmed.ncbi.nlm.nih.gov/18218160/)). Address these factors where possible, and recognize that some patients will not recover despite optimal antimicrobial selection. ## Recognized Complications and Early Detection Treatment failure in bovine respiratory disease usually follows one of several recognizable patterns. The most common is progression of fibrinous pneumonia despite apparent clinical improvement in the first 24 hours. This occurs when the initial antimicrobial suppresses but does not eliminate *Mannheimia hemolytica*, and the leukotoxin-driven inflammatory cascade continues independently of bacterial viability. Detection requires re-examination at 48 to 72 hours with specific attention to thoracic auscultation, not simply temperature and appetite. A calf that eats but develops increasing respiratory effort, auscultable crackles over the cranioventral lung fields, or a worsening fever has active pulmonary consolidation, not simple convalescence. A second pattern is relapse after apparent recovery. This typically reflects premature discontinuation of therapy, persistence of a viral cofactor such as bovine herpesvirus type 1 with its associated immunosuppression, or reinfection from an untreated penmate. The distinction matters. Relapse from premature cessation responds to a second course of the same class. Relapse from viral recrudescence requires attention to the viral component and often a longer treatment interval. Relapse from reinfection demands a group-level reassessment, including ventilation, stocking density, and the possibility of a persistently infected shedder. A third pattern is the development of chronic suppurative pneumonia or pulmonary abscessation. This presents as a calf that improves initially but never fully clears, with persistent nasal discharge, a soft productive cough, and poor growth. Thoracic ultrasound, where available, can identify abscessation and pleural involvement. These animals rarely respond to further antimicrobial therapy and should be assessed for salvage or humane euthanasia instead of subjected to prolonged treatment. ## Common Errors and Corrective Action Less experienced clinicians frequently mistake the absence of fever for the absence of infection. Pyrexia is an inconsistent finding in bovine respiratory disease, particularly in calves with chronic or viral-predominant disease. Temperature must be interpreted alongside appetite, respiratory character, and auscultation findings. A second error is treating the laboratory result instead of the animal. Nasal swab culture identifies organizms that may be commensal, and the most frequently isolated organizm in clinical disease is *M. hemolytica*, which is also a normal nasopharyngeal inhabitant. A positive culture does not confirm causation, and a negative culture does not exclude bacterial pneumonia. Culture and sensitivity are most useful when the animal has failed an appropriate first-line therapy, not as a routine screening tool. A third error is escalating antimicrobial therapy without reassessing the diagnosis. If a calf deteriorates on a reasonable first-line agent, the clinician should ask whether the problem is bacterial resistance, a non-bacterial pathogen, or a non-infectious complication such as pulmonary edema or bronchopneumonia from aspiration. Adding a second antimicrobial without this reassessment is common but frequently ineffective. | Observation | Likely cause | Discriminating check | |---|---|---| | Fever resolves, respiratory effort worsens | Fibrinous pneumonia progression | Thoracic auscultation, ultrasound if available | | Relapse 3 to 5 days after apparent recovery | Premature cessation, viral cofactor, reinfection | Review treatment duration, assess pen-level risk factors | | Persistent cough and poor growth after therapy | Pulmonary abscessation, chronic suppuration | Thoracic ultrasound, response to time instead of drugs | | Deterioration on appropriate first-line agent | Resistance, non-bacterial pathogen, non-infectious complication | Re-examine diagnosis, culture from deep sample, thoracic imaging | ## Limitations of the Evidence and Divergent Expert Opinion The evidence base for bovine respiratory disease therapy has significant gaps. Antimicrobial efficacy studies in feedlot cattle are numerous but often industry-funded, and direct comparisons between classes are limited by differences in case definitions, challenge models, and outcome measures. The variability in diagnosis and treatment regimes has been identified as a reason why antibiotic efficacy appears inconsistent across studies. Expert opinion still differs on whether metaphylaxis should be universal in high-risk cattle or reserved for groups with documented morbidity, and on the optimal duration of therapy for confirmed pneumonia. Acute phase protein measurement, including haptoglobin and serum amyloid A, has been proposed as an objective monitoring tool, and these proteins do return to baseline when the triggering factor resolves. However, their use in individual treatment decisions for bovine respiratory disease remains investigational instead of established, and they do not distinguish bacterial from viral or inflammatory causes. The clinician should treat them as adjuncts to clinical assessment, not as decision-making tests. ## Referral, Consultation, and Regulatory Reporting Most cases of bovine respiratory disease are managed on farm without specialist referral. Referral or specialist consultation is warranted when a calf fails two appropriate treatment courses, when thoracic imaging is needed to characterize suspected abscessation or pleural disease, or when the clinician suspects a pathogen with public health or trade implications. *Mycobacterium bovis* infection is primarily a respiratory disease transmitted by the airborne route, and its presentation can mimic conventional pneumonia. Suspicion of tuberculosis, based on poor response to therapy, chronic cough, or known regional risk, should trigger regulatory involvement instead of continued empirical treatment. Reporting requirements vary by jurisdiction, and the clinician should be familiar with the relevant standards for notifiable respiratory diseases in their region. Laboratory involvement is appropriate for post-mortem examination of treatment failures, particularly when multiple animals in a group fail therapy, and for culture of deep lung samples collected at necropsy instead of nasal swabs from live animals. The Davis-Thompson Foundation pathology resources and the MSD Veterinary Manual provide reference material for interpreting post-mortem findings and refining the diagnostic approach. ## Frequently Asked Questions ### How Do I Choose Therapy When Antimicrobial Cost Is the Primary Constraint? When cost limits options, prioritize a drug with proven efficacy against *Mannheimia hemolytica*, the principal bacterial isolate in bovine respiratory disease, and a dosing interval that minimizes labor [Mannheimia hemolytica and bovine respiratory disease](https://pubmed.ncbi.nlm.nih.gov/18218156/). Compare total course cost, not per-dose price, including withdrawal period effects on marketing. If a long-acting product fits the budget, it may reduce handling stress and improve compliance. When only short-acting drugs are affordable, plan for repeated handling and monitor closely for relapse. Document the financial reasoning in the record. If the animal's value is marginal, discuss salvage options with the owner before committing to a full course. ### What If I Cannot Perform Thoracic Ultrasound or Advanced Diagnostics? Treatment decisions rest on clinical examination, history, and response to therapy. Thoracic ultrasound is useful but not mandatory. In its absence, rely on serial assessment of rectal temperature, respiratory rate and effort, nasal discharge character, and appetite. The 48 to 72 hour recheck remains the central decision point. If the animal deteriorates or fails to improve, revisit the diagnosis instead of simply switching antimicrobials. Consider viral cofactors such as bovine herpesvirus type 1, which can suppress immunity and prolong disease [A review of the biology of bovine herpesvirus type 1 (BHV-1), its role as a cofactor in the bovine respiratory disease complex and development of improved vaccines](https://pubmed.ncbi.nlm.nih.gov/18218160/). When laboratory access is limited, submit nasopharyngeal swabs from the worst-affected animal to a regional laboratory for culture and susceptibility testing. ### How Does the Approach Differ for Dairy Calves Compared with Feedlot Cattle? Dairy calves are often younger, housed individually, and affected by enzootic pneumonia with a broader pathogen spectrum. Feedlot cattle are typically older, group-housed, and predominantly affected by *M. hemolytica* following viral infection and stress [Board-invited review: recent advances in management of highly stressed, newly received feedlot cattle](https://pubmed.ncbi.nlm.nih.gov/17085724/). In dairy calves, pay closer attention to failure of passive transfer, colostrum management, and environmental ventilation. In feedlot settings, group-level decisions such as metaphylaxis may be appropriate. Withdrawal periods and milk discard times differ between these production systems, so verify current label and formulary references before prescribing. The monitoring schedule is similar, but dairy calves may require more frequent reassessment given their smaller physiological reserve. ### What Records Should I Keep for Each Treated Animal? Record the animal identification, body weight, clinical findings at first examination, temperature, respiratory rate and character, and the suspected aetiology. Document the drug, dose, route, site of injection, and withdrawal period. Note the planned recheck time and the actual response at that point. Record any change in therapy and the reason for it. This documentation supports antimicrobial stewardship reviews and helps identify patterns such as poor response to a particular drug class. It also provides a defensible record if regulatory authorities request treatment histories. For group treatments, record the group size, the number treated, and the criteria used to include animals. ### How Do I Explain a Treatment Failure to the Owner? Explain that bovine respiratory disease involves multiple pathogens and that the initial drug choice is based on probability, not certainty. Viral infection often precedes bacterial pneumonia, and immune suppression can delay recovery [A review of the biology of bovine herpesvirus type 1 (BHV-1), its role as a cofactor in the bovine respiratory disease complex and development of improved vaccines](https://pubmed.ncbi.nlm.nih.gov/18218160/). State clearly what has been ruled out and what remains possible. Describe the next diagnostic step, whether that is culture, susceptibility testing, or thoracic imaging. Be honest about the limitations of current evidence on optimal second-line therapy. Agree on a cost ceiling for further investigation and treatment. If the prognosis is poor, say so directly and discuss humane endpoints. ### When Should I Suspect a Nonbacterial or Notifiable Cause? Suspect a nonbacterial cause when fever and respiratory signs persist despite appropriate antimicrobial therapy, when multiple animals fail to respond, or when the clinical pattern is unusual. Tuberculosis should be considered in chronic, progressive respiratory disease, particularly in regions or herds with known risk factors, because transmission is airborne and the host range is wide [The epidemiology of Mycobacterium bovis infections in animals and man: a review](https://pubmed.ncbi.nlm.nih.gov/7579326/). Consult the relevant veterinary authority early if a notifiable disease is possible. Acute phase protein measurement may support the presence of inflammation but does not identify a specific aetiology [Application of acute phase protein measurements in veterinary clinical chemistry](https://pubmed.ncbi.nlm.nih.gov/15099494/). When in doubt, involve a veterinary diagnostic laboratory before committing to further antimicrobial therapy. ## Related Clinical & Scientific Guides * [Hypersensitivity Reactions: Types and Mechanisms](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/hypersensitivity-reactions-types-and-mechanisms) * [Monitoring Fluid Therapy in Critically Ill Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-fluid-therapy-critically-ill-veterinary) * [Monitoring Sedation and Anesthesia Recovery in Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-sedation-anesthesia-recovery-veterinary) ## References and Further Reading - [Board-invited review: recent advances in management of highly stressed, newly received feedlot cattle.](https://pubmed.ncbi.nlm.nih.gov/17085724/). 2007. - [The epidemiology of Mycobacterium bovis infections in animals and man: a review.](https://pubmed.ncbi.nlm.nih.gov/7579326/). 1995. - [Animal models of human respiratory syncytial virus disease.](https://pubmed.ncbi.nlm.nih.gov/21571908/). 2011. - [Mannheimia hemolytica and bovine respiratory disease.](https://pubmed.ncbi.nlm.nih.gov/18218156/). 2007. - [A review of the biology of bovine herpesvirus type 1 (BHV-1), its role as a cofactor in the bovine respiratory disease complex and development of improved vaccines.](https://pubmed.ncbi.nlm.nih.gov/18218160/). 2007. - [Application of acute phase protein measurements in veterinary clinical chemistry.](https://pubmed.ncbi.nlm.nih.gov/15099494/). 2004. - [Davis-Thompson Foundation Veterinary Pathology Resources](https://www.davisthompsonfoundation.org/). Davis-Thompson Foundation. - [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual. - [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association. ## Related Articles - [Therapeutic Decision-Making for Bacterial Skin Infections in Dogs](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/therapeutic-decision-making-bacterial-skin-infections-dogs) - [Therapeutic Decision-Making for Urinary Tract Infections in Dogs](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/therapeutic-decision-making-urinary-tract-infections-dogs) - [Therapeutic Decision-Making for Autoimmune Disease in Dogs](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/therapeutic-decision-making-autoimmune-disease-dogs) - [Therapeutic Decision-Making for Gastrointestinal Ulcers in Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/therapeutic-decision-making-gastrointestinal-ulcers-veterinary) - [Therapeutic Decision Frameworks for Veterinary Inflammation](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/therapeutic-decision-frameworks-veterinary-inflammation) > This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.